Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat cancers: drug targets HER2 mutations

NCT ID NCT04639219

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with advanced solid tumors that have a specific HER2 gene mutation. The goal is to see if the drug can shrink tumors in patients who have already tried other treatments. The study includes 102 adults with various cancer types, such as colorectal, bladder, stomach, and others.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Santa Rosa, California, 95403, United States

  • Research Site

    Muncie, Indiana, 47303, United States

  • Research Site

    Boston, Massachusetts, 02115, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    Middletown, New Jersey, 07748, United States

  • Research Site

    Commack, New York, 11725, United States

  • Research Site

    Harrison, New York, 10604, United States

  • Research Site

    New York, New York, 10021, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Anderlecht, 1070, Belgium

  • Research Site

    Toronto, CA, M5G 2M9, Canada

  • Research Site

    Copenhagen, 2100, Denmark

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Lyon, 69008, France

  • Research Site

    Villejuif, 94805, France

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Milan, 20162, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Suita-shi, 565-0871, Japan

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Seville, 41013, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST